Dear Editor, We read with great interest the letter to the editor entitled "Obstructive sleep apnea and dyslipidemia: importance of the liver axis" [1] in response to our recent paper addressing dyslipidemia in obstructive sleep apnea (OSA) [2] . The authors emphasized the importance of the liver axis in the pathogenesis of OSA-induced dyslipidemia and referenced the theoretical possibility of the liver as a potential target for intervention. We are grateful for their interest in this topic which further underscores its importance.
We summarized the data on the liver pathways in the section on pathophysiological mechanisms and Fig. 1 of our paper [2] . However, the point is noted that OSA may be independently associated with insulin resistance and type-2 diabetes as well. Although it has been proposed that induction of phospholipids and triglyceride production by hypoxia-inducible factor (HIF) in the liver is due to sterol regulatory element binding protein-1 (SREBP-1) independent of SREBP-2 which is responsible for cholesterol production via the 3-hydroxy-3-methylglutaryl CoA reductase [3] . However, the mechanisms of HIF and SREBP-1 activation in the liver by chronic intermittent hypoxia from OSA are not completely understood. While we also discussed the role of OSA-induced sympathetic activation in the development of dyslipidemia, we acknowledge that the role of hormone-sensitive lipase is central to peripheral lipolysis from adipose tissue which is responsible for most of the free fatty acid presented to the liver for lipoprotein generation [4] .
Of note, we discussed multiple pathways including activation of the sympathetic autonomic nervous system that have been proposed for OSA-induced dyslipidemia [2] , but most importantly, we emphasized that a direct cause and effect relationship is yet to be established. Therefore, there is a need for more studies to precisely define the relationship between OSA and dyslipidemia and determine potential targets for intervention.
